Rock Springs Capital Management LP Purchases New Position in Homology Medicines (FIXX)

Rock Springs Capital Management LP bought a new position in shares of Homology Medicines (NASDAQ:FIXX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 575,000 shares of the company’s stock, valued at approximately $10,753,000. Rock Springs Capital Management LP owned 1.59% of Homology Medicines as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in FIXX. Temasek Holdings Private Ltd purchased a new stake in Homology Medicines in the 1st quarter valued at about $60,219,000. JPMorgan Chase & Co. bought a new stake in shares of Homology Medicines in the 1st quarter worth approximately $22,772,000. Franklin Resources Inc. bought a new stake in shares of Homology Medicines in the 1st quarter worth approximately $6,078,000. Lord Abbett & CO. LLC bought a new stake in shares of Homology Medicines in the 1st quarter worth approximately $3,740,000. Finally, Sphera Funds Management LTD. bought a new stake in shares of Homology Medicines in the 1st quarter worth approximately $2,487,000. Hedge funds and other institutional investors own 48.46% of the company’s stock.

Several research firms recently weighed in on FIXX. Evercore ISI began coverage on Homology Medicines in a research report on Monday, April 23rd. They set an “outperform” rating and a $30.00 price target on the stock. Cowen began coverage on Homology Medicines in a research report on Monday, April 23rd. They issued an “outperform” rating for the company. BTIG Research began coverage on Homology Medicines in a research report on Tuesday, April 24th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Bank of America began coverage on Homology Medicines in a research report on Monday, April 23rd. They set a “buy” rating and a $27.00 target price for the company.

Shares of Homology Medicines traded up $0.15, hitting $18.81, during midday trading on Tuesday, according to MarketBeat. The stock had a trading volume of 700 shares, compared to its average volume of 124,785. Homology Medicines has a fifty-two week low of $16.12 and a fifty-two week high of $24.40.

Homology Medicines (NASDAQ:FIXX) last posted its earnings results on Monday, May 14th. The company reported ($4.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.78) by ($0.43). The business had revenue of $0.82 million during the quarter. equities research analysts expect that Homology Medicines will post -1.74 EPS for the current year.

In related news, insider James E. Flynn purchased 1,250,000 shares of the stock in a transaction dated Monday, April 2nd. The stock was bought at an average cost of $16.00 per share, for a total transaction of $20,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Vida Ventures, Llc purchased 375,000 shares of the stock in a transaction dated Monday, April 2nd. The shares were bought at an average price of $16.00 per share, with a total value of $6,000,000.00. The disclosure for this purchase can be found here.

About Homology Medicines

There is no company description available for Homology Medicines Inc

Institutional Ownership by Quarter for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply